Immuno-virological and Clinical Follow-up of Persons Living With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study

Véronique Joly; Valentine M Ferre; Quentin Le Hingrat; Gilles Peytavin; Mélanie Cresta; Charlotte Charpentier; Marc Digumber; Florence Damond; Yazdan Yazdanpanah; Sophie Matheron; Diane Descamps; Jade Ghosn

doi:10.1093/cid/ciae447

Immuno-virological and Clinical Follow-up of Persons Living With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study

Clin Infect Dis. 2024 Sep 16:ciae447. doi: 10.1093/cid/ciae447. Online ahead of print.

Affiliations

¹ IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard, AP-HP, Paris, France.
² IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP Laboratoire de Virologie, Hôpital Bichat Claude Bernard, AP-HP, Paris, France.
³ IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Pharmacologie-Toxicologie, Hôpital Bichat Claude Bernard, AP-HP, Paris, France.

PMID: 39283963
DOI: 10.1093/cid/ciae447

Abstract

This retrospective study evaluated Bictegravir/FTC/TAF in 24 PWHIV, 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load < 40 copies/mL. Median CD4 count increased significantly from 580 to 625 cells/mm3, suggesting the effectiveness of Bictegravir/FTC/TAF to treat HIV-2 infection.

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].